1
TÍTULO: Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma  Full Text
AUTORES: Xavier Leleu; Tamas Masszi; Nizar J Bahlis; Luisa Viterbo; Bartrum Baker; Peter Gimsing; Vladimir Maisnar; Olga Samoilova; Laura Rosinol; Christian Langer; Kevin Song; Tohru Izumi; Charles Cleeland; Deborah Berg; Huamao Mark Lin; Yanyan Y Zhu; Tomas Skacel; Philippe Moreau; Paul G Richardson;
PUBLICAÇÃO: 2018, FONTE: AMERICAN JOURNAL OF HEMATOLOGY, VOLUME: 93, NÚMERO: 8
INDEXADO EM: Scopus WOS
2
TÍTULO: Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution  Full Text
AUTORES: Nuno Cerveira; Bruno Loureiro; Susana Bizarro; Cecilia Correia; Lurdes Torres; Susana Lisboa; Joana Vieira; Rui Santos; Dulcineia Pereira; Claudia Moreira; Sergio Chacim; Nelson Domingues; Ana Espirito Santo; Isabel Oliveira; Ilidia Moreira; Luisa Viterbo; Angelo Martins; Manuel R Teixeira ; Jose M Mariz;
PUBLICAÇÃO: 2018, FONTE: BMC CANCER, VOLUME: 18, NÚMERO: 1
INDEXADO EM: Scopus WOS CrossRef: 14
3
TÍTULO: Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1  Full Text
AUTORES: Maria Victoria Mateos; Tamas Masszi; Norbert Grzasko; Markus Hansson; Irwindeep Sandhu; Ludek Pour; Luisa Viterbo; Sharon R Jackson; Anne Marie Stoppa; Peter Gimsing; Mehdi Hamadani; Gabriela Borsaru; Deborah Berg; Jianchang C Lin; Alessandra Di Bacco; Helgi van de Velde; Paul G Richardson; Philippe Moreau;
PUBLICAÇÃO: 2017, FONTE: HAEMATOLOGICA, VOLUME: 102, NÚMERO: 10
INDEXADO EM: Scopus WOS
4
TÍTULO: Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia
AUTORES: Ana Espirito Santo; Sergio Chacim; Isabel Ferreira; Luis Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas; Marta Nunes; Luisa Viterbo; Ilidia Moreira; Angelo Martins; Isabel Oliveira; Nelson Domingues; Jose Mariz; Rui Medeiros ;
PUBLICAÇÃO: 2017, FONTE: MOLECULAR AND CLINICAL ONCOLOGY, VOLUME: 6, NÚMERO: 3
INDEXADO EM: WOS CrossRef: 3
5
TÍTULO: Efficacy and safety of ixazomib plus lenalidomidedexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
AUTORES: Paul G Richardson; Herve Avet Loiseau; Antonio Palumbo; Luisa Viterbo; Arnon Nagler; Peter Ganly; Dina Ben Yehuda; Jesus San Miguel; Vincent V Rajkumar; Ludek Pour; Christian Langer; Nizar J Bahlis; Andrzej Pluta; Tamas Masszi; Deborah Berg; Jianchang C Lin; Helgi Van De Velde; Dixie Lee Esseltine; Alessandra di Baccot; Philippe Moreau;
PUBLICAÇÃO: 2016, FONTE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 34, NÚMERO: 15
INDEXADO EM: WOS
6
TÍTULO: Coexistence of alternative MLL-SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25)  Full Text
AUTORES: Joana Santos; Nuno Cerveira ; Cecilia Correia; Susana Lisboa; Manuela Pinheiro; Lurdes Torres; Susana Bizarro; Joana Vieira; Luisa Viterbo; Jose M Mariz; Manuel R Teixeira ;
PUBLICAÇÃO: 2010, FONTE: CANCER GENETICS AND CYTOGENETICS, VOLUME: 197, NÚMERO: 1
INDEXADO EM: Scopus WOS CrossRef: 11
7
TÍTULO: Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial  Full Text
AUTORES: Natacha Heutte; Henning H Flechtner; Nicolas Mounier; Wilhelmina A M Mellink; Jacobus H Meerwaldt; Houchingue Eghbali; Mars B van't Veer; Evert M Noordijk; Johanna C Kluin Nelemans; Elzbieta Lampka; Jose Thomas; Pieternella J Lugtenburg; Luisa Viterbo; Patrice Carde; Anton Hagenbeek; Richard W M van der Maazen; Wilma G J M Smit; Pauline Brice; Marinus van Marwijk Kooy; Johanna W Baars; Philip Poortmans; Umberto Tirelli; Onno C Leeksma; Radka Tomsic; Pierre Feugier; Gilles Salles; Jean Gabarre; Marie Jose Kersten; Eric Van Den Neste; Geert Jan M Creemers; Isabelle Gaillard; Paul Meijnders; Gerard Tertian; Oumedaly Reman; Hein P Muller; Jacques Troncy; Michel Blanc; Wilfried Schroyens; Paul J Voogt; Pierre Wijermans; Chantal Rieux; Christophe Ferme; Michel Henry Amar; ...Mais
PUBLICAÇÃO: 2009, FONTE: LANCET ONCOLOGY, VOLUME: 10, NÚMERO: 12
INDEXADO EM: Scopus WOS CrossRef
8
TÍTULO: Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.
AUTORES: Heinz Ludwig; Luisa Viterbo; Richard Greil; Tamas Masszi; Ivan Spicka; Ofer Shpilberg; Roman Hajek; Anna Dmoszynska; Andrew Cakana; Christopher Enny; Huaibao B Feng; Helgi van de Velde; Jean Luc Harousseau;
PUBLICAÇÃO: 2009, FONTE: 51st Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 114, NÚMERO: 22
INDEXADO EM: WOS